OTR acting director
Executive Summary
FDA Office of Testing & Research Division of Pharmaceutical Analysis Director Cindy Buhse succeeds Ajaz Hussain as OTR acting director effective Oct. 31. Buhse has worked at the agency since 2001. Hussain, who also served as deputy director of the Office of Pharmaceutical Science, left FDA Oct. 28 to become VP-biopharmaceutical development at Sandoz (1"The Pink Sheet" Oct. 10, 2005, p. 3)...
You may also be interested in...
New OTR director
FDA appoints Vincent Vilker as director of the Office of Testing and Research, within the Office of Pharmaceutical Science. Vilker replaces Ajaz Hussain, who left FDA in October to become VP-biopharmaceutical development at Sandoz (1"The Pink Sheet" Oct. 31, 2005, In Brief). Vilker hails from the National Institute of Standards where he served as chief of the biotechnology division...
FDA Implementing New CMC Review Process Through Revamped Office
FDA is changing its review of chemistry, manufacturing and controls submissions with a new quality assessment office that will involve greater staff specialization
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.